LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Home・Aandelen Lijst・Merus NV

Merus NV

Gesloten

SectorGezondheidszorg

96.65 0.04

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

96.51

Max

96.76

Belangrijke statistieken
By Trading Economics
Inkomsten	63M -96M
Verkoop	2.9M 10M
EPS	-1.26
Winstmarge	-920.804
Werknemers	260
EBITDA	17M -76M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+0.97% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	133M 7.3B
Vorige openingsprijs	96.61
Vorige sluitingsprijs	96.65

Nieuwssentiment

By Acuity

50%

187 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

39.445 / 44.36 Steun & Weerstand

Merus NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 dec 2025, 23:58 UTC

Acquisities, Fusies, Overnames

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11 dec 2025, 23:56 UTC

Winsten

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11 dec 2025, 23:03 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11 dec 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dec 2025, 21:50 UTC

Winsten

Costco Same-Store Sales, Membership Fees Rose in 1Q

11 dec 2025, 23:45 UTC

Marktinformatie

Global Equities Roundup: Market Talk

11 dec 2025, 23:44 UTC

Marktinformatie

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11 dec 2025, 23:37 UTC

Marktinformatie

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11 dec 2025, 23:31 UTC

Winsten

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dec 2025, 22:48 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11 dec 2025, 22:35 UTC

Winsten

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11 dec 2025, 22:30 UTC

Winsten

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11 dec 2025, 22:09 UTC

Acquisities, Fusies, Overnames

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11 dec 2025, 22:06 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11 dec 2025, 22:05 UTC

Winsten

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dec 2025, 21:51 UTC

Acquisities, Fusies, Overnames

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

11 dec 2025, 21:39 UTC

Winsten

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11 dec 2025, 21:39 UTC

Winsten

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11 dec 2025, 21:38 UTC

Winsten

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11 dec 2025, 21:37 UTC

Winsten

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11 dec 2025, 21:37 UTC

Marktinformatie

Broadcom Sees AI Revenue Doubling -- Market Talk

11 dec 2025, 21:34 UTC

Acquisities, Fusies, Overnames

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

Dexus Aiming for Long-Term Holding of A$50M in Fund

11 dec 2025, 21:28 UTC

Marktinformatie

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Dexus: Third Party Investors to Contribute Remainder

11 dec 2025, 21:27 UTC

Acquisities, Fusies, Overnames

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11 dec 2025, 21:25 UTC

Acquisities, Fusies, Overnames

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Peer Vergelijking

Prijswijziging

Merus NV Prognose

Koersdoel

By TipRanks

0.97% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 97.71 USD 0.97%

Hoogste 112 USD

Laagste 92 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merus NV - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

16 ratings

Buy

Hold

Sell

Gebaseerd op 16 analisten die aandelenratings hebben gegeven aan Merus NV - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

39.445 / 44.36Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

187 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.